Deformable Nanovesicles for Blood-Brain Barrier and Transdermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems often fail to effectively target specific sites within the body, leading to systemic toxicity and reduced efficacy, necessitating a localized delivery system to enhance drug effectiveness and reduce adverse effects.
Innovation Solution
Development of deformable nano-scale vehicles (DNVs) comprising amphipathic vesicle-forming lipids, cholesterol, and non-ionic detergents, which can include therapeutic agents like flavonoids, resveratrol, antibodies, and miRNAs, capable of transdermal delivery and crossing the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug delivery systems are used, then drugs can be administered systemically, but they cause systemic toxicity and reduced efficacy at target sites
Solution Approach 1:
The drug delivery system is segmented into nanoscale vehicles (50-200 nm) that can be selectively targeted to specific tissues and cells. The patent divides the drug delivery function into discrete nanoparticle carriers that transport drugs to target sites while avoiding systemic distribution, thereby reducing toxicity and improving efficacy.
Solution Approach 2:
The patent applies local quality by creating drug delivery vehicles with surface modifications that provide selective targeting capabilities. Different nanoparticles can be functionalized with specific ligands, antibodies, or peptides that recognize target tissues, ensuring the drug is delivered locally rather than systemically.
2Productivity
If transdermal delivery systems are used, then drug penetration through skin is achieved, but transport efficiency and safety are insufficient
Solution Approach 1:
The patent uses composite nanomaterials combining lipid bilayers with polymer coatings and surface-functionalized particles. These composite structures provide both the penetration capability needed for transdermal delivery and the safety features of controlled release and biocompatibility.
Solution Approach 2:
The patent employs parameter changes by adjusting nanoparticle size (50-200 nm), surface charge, and hydrophobicity to optimize both skin penetration efficiency and safety. The nanoscale dimensions and surface properties are specifically tuned to enhance transdermal transport while maintaining biocompatibility.
3Reliability
If localized drug delivery is implemented, then efficacy at target site is improved, but delivery system complexity increases
Solution Approach 1:
The patent develops universal nanocarrier platforms that can deliver multiple types of drugs (small molecules, proteins, nucleic acids) through various routes (transdermal, oral, intravenous). This multi-functionality reduces the need for separate complex systems for different drug types and delivery routes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DNVs provide targeted drug delivery, enhancing efficacy at the site of action while minimizing systemic toxicity, thereby improving patient compliance and outcomes.
Implementation Method 1
one or more amphipathic vesicle-forming lipids
Implementation Method 2
amphipathic vesicle-forming lipids; cholesterol; and a non-ionic detergent
Implementation Method 3
capable of transdermal delivery and can additionally cross the blood-brain barrier
Implementation Method 4
delivery of therapeutic agents
Data Source
AI summary
In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.